WO2008090209A3 - Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders - Google Patents
Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders Download PDFInfo
- Publication number
- WO2008090209A3 WO2008090209A3 PCT/EP2008/050850 EP2008050850W WO2008090209A3 WO 2008090209 A3 WO2008090209 A3 WO 2008090209A3 EP 2008050850 W EP2008050850 W EP 2008050850W WO 2008090209 A3 WO2008090209 A3 WO 2008090209A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glucopyranosyloxy
- preventing
- neurodegenerative disorders
- pyrazoles
- treating neurodegenerative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
The present invention relates to the use of a glucopyranosyloxy-pyrazole as defined in claim 1 for the manufacture of a medicament for treating, preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders in a patient in need thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07101213 | 2007-01-26 | ||
EP07101213.2 | 2007-01-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008090209A2 WO2008090209A2 (en) | 2008-07-31 |
WO2008090209A3 true WO2008090209A3 (en) | 2008-10-02 |
Family
ID=39315016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/050850 WO2008090209A2 (en) | 2007-01-26 | 2008-01-25 | Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR065034A1 (en) |
CL (1) | CL2008000223A1 (en) |
TW (1) | TW200843785A (en) |
WO (1) | WO2008090209A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
EP2582709B1 (en) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003020737A1 (en) * | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
WO2005021566A2 (en) * | 2003-08-26 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy- pirazoles, drugs containing said compounds the use and production method thereof |
WO2006058597A1 (en) * | 2004-12-03 | 2006-06-08 | Merck Patent Gmbh | Tetrahydropyrane derivatives for use as antidiabetics |
WO2006062224A1 (en) * | 2004-12-07 | 2006-06-15 | Takeda Pharmaceutical Company Limited | Carboxamide derivative |
WO2006127842A2 (en) * | 2005-05-23 | 2006-11-30 | The Regents Of The University Of California | Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease |
WO2007014895A2 (en) * | 2005-07-28 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives |
-
2008
- 2008-01-25 CL CL200800223A patent/CL2008000223A1/en unknown
- 2008-01-25 TW TW097102900A patent/TW200843785A/en unknown
- 2008-01-25 AR ARP080100311A patent/AR065034A1/en unknown
- 2008-01-25 WO PCT/EP2008/050850 patent/WO2008090209A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003020737A1 (en) * | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
WO2005021566A2 (en) * | 2003-08-26 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy- pirazoles, drugs containing said compounds the use and production method thereof |
WO2006058597A1 (en) * | 2004-12-03 | 2006-06-08 | Merck Patent Gmbh | Tetrahydropyrane derivatives for use as antidiabetics |
WO2006062224A1 (en) * | 2004-12-07 | 2006-06-15 | Takeda Pharmaceutical Company Limited | Carboxamide derivative |
WO2006127842A2 (en) * | 2005-05-23 | 2006-11-30 | The Regents Of The University Of California | Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease |
WO2007014895A2 (en) * | 2005-07-28 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Week 200645, Derwent World Patents Index; AN 2006-445878, XP002487051 * |
Also Published As
Publication number | Publication date |
---|---|
AR065034A1 (en) | 2009-05-13 |
WO2008090209A2 (en) | 2008-07-31 |
TW200843785A (en) | 2008-11-16 |
CL2008000223A1 (en) | 2008-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008090209A3 (en) | Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders | |
UA108198C2 (en) | Substituted 2-acetamido-5-aryl-l, 2,4-triazolones and their use | |
WO2006116221A3 (en) | Therapeutic combinations for the treatment or prevention of psychotic disorders | |
JO2756B1 (en) | 4T 4-(4- Cyano-2-thioaryl)dihydropyrimidinones and use thereof | |
ZA200807879B (en) | Use of bifidobacterium longum for the prevention and treatment of inflammation | |
WO2009129246A3 (en) | Compositions and methods for preparing and using same | |
WO2008104306A3 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | |
WO2008137633A3 (en) | Methods of modulating cellular homeostatic pathways and cellular survival | |
WO2007127263A3 (en) | Therapeutic uses of urolithins | |
IN2015DN00502A (en) | ||
WO2008061720A3 (en) | Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders | |
WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
WO2008052139A3 (en) | Ultra low dose doxepin and methods of using the same to treat sleep disorders | |
WO2009141541A3 (en) | Use of kif13a and ap-1 inhibitors for inhibiting melanogenesis | |
UA102238C2 (en) | 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof | |
WO2008079993A3 (en) | Combinations of nitric oxide and sulfide and methods of use and manufacture thereof | |
WO2009035634A3 (en) | Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors | |
WO2007144057A3 (en) | Antimicrobial carbon | |
WO2009140675A3 (en) | Combination therapy with pm00104 and another antitumor agent | |
WO2007017146A3 (en) | Use of collismycin and derivatives thereof as oxidative stress inhibitors | |
WO2009123486A8 (en) | Use of compounds in the treatment of tau-induced cytotoxicities | |
WO2008094054A3 (en) | 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders | |
WO2011041325A3 (en) | Methods and compositions for the treatment of viral disorders | |
EP2193789A4 (en) | The application of 3, 5-dihydroxytoluene or derivatives thereof in the preparation of medicine and functional for treating or preventing depression. | |
WO2008050133A3 (en) | Inhibition of beta-amyloid aggregation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08701663 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08701663 Country of ref document: EP Kind code of ref document: A2 |